<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000670</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 107</org_study_id>
    <secondary_id>11082</secondary_id>
    <nct_id>NCT00000670</nct_id>
  </id_info>
  <brief_title>Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks</brief_title>
  <official_title>Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the interaction of probenecid with zidovudine (AZT). Because AZT is eliminated&#xD;
      quickly from the body, it must be taken frequently. A previous study showed that probenecid&#xD;
      slowed the elimination of AZT without side effects, but that study lasted only 5 days. This&#xD;
      study is to see whether this effect continues for 1 month and whether the continuation of&#xD;
      probenecid and AZT is free of side effects over 1 month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because AZT is eliminated quickly from the body, it must be taken frequently. A previous&#xD;
      study showed that probenecid slowed the elimination of AZT without side effects, but that&#xD;
      study lasted only 5 days. This study is to see whether this effect continues for 1 month and&#xD;
      whether the continuation of probenecid and AZT is free of side effects over 1 month.&#xD;
&#xD;
      Patients are hospitalized overnight on three separate occasions. On the first admission, AZT&#xD;
      is administered every 4 hours. On the second day, 15 blood samples are taken to determine how&#xD;
      fast the AZT enters and is removed from the bloodstream (pharmacokinetics). On the second&#xD;
      day, after all the blood specimens have been collected, patient starts taking probenecid by&#xD;
      mouth every 8 hours, and is discharged from the research unit. The AZT dose is then taken&#xD;
      every 8 hours. One week later and again 3 weeks after that, patient is readmitted overnight&#xD;
      and the blood sampling to measure AZT levels is repeated. AMENDED: 8 additional patients will&#xD;
      be enrolled using the same doses of AZT but a lower dose of probenecid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">July 1989</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>16</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Radiation for skin lesions.&#xD;
&#xD;
        Patients with symptomatic HIV infection taking zidovudine (AZT) five or six times a day as&#xD;
        therapy. Includes patients with AIDS who have history of cytologically confirmed&#xD;
        Pneumocystis carinii pneumonia (PCP), patients with advanced AIDS related complex (ARC),&#xD;
        and HIV antibody positive patients.&#xD;
&#xD;
        Patients must be able to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Allergy to probenecid.&#xD;
&#xD;
          -  Any underlying medical condition sufficient, in the investigator's opinion, to prevent&#xD;
             adequate compliance with study therapy.&#xD;
&#xD;
          -  History of urinary tract urate stones or gout.&#xD;
&#xD;
          -  Becoming acutely ill, unstable, or febrile.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Methotrexate.&#xD;
&#xD;
          -  Antiretroviral drugs.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Amphotericin.&#xD;
&#xD;
          -  Experimental drugs.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Pyrazinamide.&#xD;
&#xD;
          -  Flucytosine.&#xD;
&#xD;
          -  Intravenous pentamidine.&#xD;
&#xD;
          -  Dapsone.&#xD;
&#xD;
          -  Fansidar.&#xD;
&#xD;
          -  Antineoplastic drugs not specifically allowed.&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole.&#xD;
&#xD;
          -  Valproic acid.&#xD;
&#xD;
          -  Opiates.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Sulfonylureas.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation not specifically allowed.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Allergy to probenecid.&#xD;
&#xD;
          -  Any underlying medical condition sufficient, in investigator's opinion, to prevent&#xD;
             adequate compliance with study therapy.&#xD;
&#xD;
          -  History of urinary tract urate stones or gout.&#xD;
&#xD;
          -  Becoming acutely ill, unstable, or febrile.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BG Petty</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>DM Kornhauser</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>PS Lietman</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>JG Bartlett</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>UCD Med Ctr</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wong SL, Hedaya MA, Sawchuk RJ. Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration. Pharm Res. 1992 Feb;9(2):228-35. doi: 10.1023/a:1018993524818.</citation>
    <PMID>1553347</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probenecid</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

